{'fraction_non_alphanumeric': 0.032586558044806514, 'fraction_numerical': 0.018329938900203666, 'mean_word_length': 5.597315436241611, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low-Dosage Oral Progestogens to Control Fertility: I. Clinical Investigation

The clinical contraceptive value of four oral progestogens was studied in two forms: a) low-dosage, continuous (1472 women during 13,875 months); b) the same compounds at higher doses, but taken only before coitus (333 women, 1830 months). Subjects were of comparable age, parity, socioeconomic and educational backgrounds. The precoital regimen was better tolerated, with less bleeding and cycle disturbance. Efficacy seems related to the agent and dosage administered. Norgestrienone and Clogestone showed higher efficacy in both regimens than did Retroprogestagen and Ethynodiol diacetate. Modifications in cervical mucus, sperm tolerance, endometrium, and urinary pregnanediol were frequent but not constant. In 60% of subjects accepted for elective tubal sterilization, signs of ovulation were found. Coital use of progestogens seems possible and effective if the proper compound and dose are given.